×
About 1,088 results

ALLMedicine™ Atypical Hemolytic Uremic Syndrome Center

Research & Reviews  397 results

Differentiating Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome and ...
https://doi.org/10.1161/HYPERTENSIONAHA.121.17311
Hypertension (Dallas, Tex. : 1979); Burwick RM, Moyle K et. al.

Jul 19th, 2021 - Pregnancy-associated atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy which may be mistaken for hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. We sought to identify laboratory ...

Functional characterization of 105 Factor H variants associated with atypical HUS: less...
https://doi.org/10.1182/blood.2021012037
Blood Martin Merinero H, Zhang Y et. al.

Jun 30th, 2021 - Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy that can progress, when untreated, to end-stage renal disease. Most frequently, aHUS is caused by complement dysregulation due to pathogenic variants in gen...

COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolyti...
https://doi.org/10.1007/s40620-021-01057-3 10.1016/j.jinf.2020.03.037 10.1016/j.kint.2020.05.013 10.1182/blood.2020008248 10.1161/CIRCULATIONAHA.120.047419 10.1056/NEJMoa1208981 10.1016/j.phrs.2020.105250 10.1016/j.eclinm.2020.100590 10.1093/ckj/sfaa166 10.1016/j.kint.2020.10.030
Journal of Nephrology; Cognard N, Gautier-Vargas G et. al.

May 17th, 2021 - COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report.|2021|Cognard N,Gautier-Vargas G,Perrin P,Benotmane I,Caillard S,|

It takes two to thrombosis: Hemolysis and complement.
https://doi.org/10.1016/j.blre.2021.100834
Blood Reviews; Delvasto-Nuñez L, Jongerius I et. al.

May 14th, 2021 - Thromboembolic events represent the most common complication of hemolytic anemias characterized by complement-mediated hemolysis such as paroxysmal nocturnal hemoglobinuria and autoimmune hemolytic anemia. Similarly, atypical hemolytic uremic synd...

see more →

Guidelines  3 results

Clinical guides for atypical hemolytic uremic syndrome in Japan.
https://doi.org/10.1007/s10157-016-1276-6
Clinical and Experimental Nephrology; Kato H, Nangaku M et. al.

Jul 16th, 2016 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely ...

An international consensus approach to the management of atypical hemolytic uremic synd...
https://doi.org/10.1007/s00467-015-3076-8
Pediatric Nephrology (Berlin, Germany); Loirat C, Fakhouri F et. al.

Apr 10th, 2015 - Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g....

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic urem...
https://doi.org/10.1007/s00467-008-0964-1
Pediatric Nephrology (Berlin, Germany); Ariceta G, Besbas N et. al.

Sep 18th, 2008 - This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the current ability to identify the etiology of specific...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  6 results

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
https://clinicaltrials.gov/ct2/show/NCT03205995

Oct 17th, 2018 - This is a Phase 3, multicenter study of OMS721 in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The uncontrolled, open-label study will evaluate the effect of OMS721 in subjects with plasma therapy-resistant aHUS and plasm...

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT03518203

Sep 2nd, 2018 - This clinical trial is a prospective single arm multi-institution study in children and young adults undergoing allogeneic or autologous hematopoietic stem cell transplantation who will receive early therapy with eculizumab to prevent TMA-associat...

Complement Inhibition in aHUS Dialysis Patients
https://clinicaltrials.gov/ct2/show/NCT02464891

Nov 13th, 2017 - Inherited defects that determine uncontrolled activation of the alternative complement pathway have been well documented in atypical Hemolytic Uremic Syndrome (aHUS) patients. Research in recent years has identified more than 120 different mutatio...

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
https://clinicaltrials.gov/ct2/show/NCT00838513

Jul 22nd, 2015 - The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
https://clinicaltrials.gov/ct2/show/NCT01770951

Jan 17th, 2013 - The objective of this retrospective trial is to assess safety and efficacy of eculizumab in aHUS patients treated outside of an Alexion-sponsored controlled clinical trial.

see more →

News  26 results

Alexion to study rare blood-disorder drug in severe COVID-19 patients
https://www.reuters.com/article/us-health-coronavirus-alexion-pharms/alexion-to-study-rare-blood-disorder-drug-in-severe-covid-19-patients-idUSKBN2221PM

Apr 20th, 2020 - (Reuters) - Alexion Pharmaceuticals Inc said on Monday it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome. The study is expec...

FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome
https://www.medscape.com/viewarticle/920120

Oct 20th, 2019 - The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 month or older with atypical hemolytic uremic synd...

PREVENT: Eculizumab May Lower Relapse Risk in NMOSD
https://www.staging.medscape.com/viewarticle/912600

May 3rd, 2019 - PHILADELPHIA — Intravenous eculizumab (Soliris, Alexion Pharmaceuticals) significantly decreased risk for relapse in patients with neuromyelitis optical spectrum disorder (NMOSD) over placebo, in a new multicountry phase 3 study. Findings from PRE...

Morning Break: More Guns, More Kid Deaths; Culture Change; FDA's 2018 Record
https://www.medpagetoday.com/pediatrics/generalpediatrics/77684

Jan 29th, 2019 - Note that some links may require subscriptions. Researchers linked handgun ownership to an increase in child deaths. (CNN Health, Pediatrics) The FDA boasted that 2018 was a "record year for device innovation" with 106 novel products approved, up ...

OMS721 gains orphan designation for HSCT-associated thrombotic microangiopathy
https://www.mdedge.com/hematology-oncology/article/178248/transfusion-medicine/oms721-gains-orphan-designation-hsct
Jennifer Smith

Oct 26th, 2018 - The Food and Drug Administration has granted OMS721 orphan designation for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-TMA). OMS721 is a monoclonal antibody targeting MASP-2, the effector enzyme.

see more →